Gut Microbiota, Peroxisome Proliferator-Activated Receptors, and Hepatocellular Carcinoma

Overview

Journal J Hepatocell Carcinoma

Date 2020 Nov 5

PMID 33150145

Citations 11

Authors

Qiang Yu

Liwei Wu

Jie Ji

Jiao Feng

Weiqi Dai

Jingjing Li

Jianye Wu

Chuanyong Guo

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world. HCC incidence rate is sixth and mortality is fourth worldwide. However, HCC pathogenesis and molecular mechanisms remain unclear. The incidence of HCC is associated with genetic, environmental, and metabolic factors. The role of gut microbiota in the pathogenesis of HCC has attracted researchers' attention because of anatomical and functional interactions between liver and intestine. Studies have demonstrated the involvement of gut microbiota in the development of HCC and chronic liver diseases, such as alcoholic liver disease (ALD), nonalcoholic fatty liver disease (NAFLD), and liver cirrhosis. Peroxisome proliferator-activated receptors (PPARs) are a group of receptors with diverse biological functions. Natural and synthetic PPAR agonists show potential for treatment of NAFLD, liver fibrosis, and HCC. Recent studies have demonstrated that PPARs take part in gut microbiota inhabitation and adaptation. This manuscript reviews the role of gut microbiota in the development of HCC and precancerous diseases, the role of PPARs in modulation of gut microbiota and HCC, and potential of gut microbiota for HCC diagnosis and treatment.

Citing Articles

Identification of PIF1 as a Ferroptosis-Related Prognostic Biomarker Correlated with Immune Infiltration in Hepatocellular Carcinoma.

Liu F, Yin P, Lu L, Yao J, Jiao B Appl Biochem Biotechnol. 2025; .

PMID: 39888492 DOI: 10.1007/s12010-024-05161-5.

New Insights into the Pathogenesis of Alcoholic Liver Disease Based on Global Research.

Zhang J, Yang Z, Liu X, Yang X, Li Y, Jin X Dig Dis Sci. 2025; .

PMID: 39806089 DOI: 10.1007/s10620-024-08778-y.

Development of a promising PPAR signaling pathway-related prognostic prediction model for hepatocellular carcinoma.

Shi Q, Zeng Y, Xue C, Chu Q, Yuan X, Li L Sci Rep. 2024; 14(1):4926.

PMID: 38418897 PMC: 10902383. DOI: 10.1038/s41598-024-55086-6.

The Role of Gut Microbiome in Hepatocellular Carcinoma: A Systematic Review.

Trivedi Y, Bolgarina Z, Desai H, Senaratne M, Swami S, Aye S Cureus. 2023; 15(8):e43862.

PMID: 37614827 PMC: 10442465. DOI: 10.7759/cureus.43862.

Gut microbiota modulation in patients with non-alcoholic fatty liver disease: Effects of current treatments and future strategies.

Maestri M, Santopaolo F, Pompili M, Gasbarrini A, Ponziani F Front Nutr. 2023; 10:1110536.

PMID: 36875849 PMC: 9978194. DOI: 10.3389/fnut.2023.1110536.

References

Feng J, Dai W, Mao Y, Wu L, Li J, Chen K . Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis. J Exp Clin Cancer Res. 2020; 39(1):24. PMC: 6993409. DOI: 10.1186/s13046-020-1528-x. View

Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, Karamanolis D, Ladas S . Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol. 2012; 28(3):450-5. DOI: 10.1111/jgh.12070. View

Dubinkina V, Tyakht A, Odintsova V, Yarygin K, Kovarsky B, Pavlenko A . Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease. Microbiome. 2017; 5(1):141. PMC: 5645934. DOI: 10.1186/s40168-017-0359-2. View

Feng J, Chen K, Xia Y, Wu L, Li J, Li S . Salidroside ameliorates autophagy and activation of hepatic stellate cells in mice via NF-κB and TGF-β1/Smad3 pathways. Drug Des Devel Ther. 2018; 12:1837-1853. PMC: 6021006. DOI: 10.2147/DDDT.S162950. View

Hsiao C, Chen P, Cheng C, Tsai M, Chang C, Lu S . Toll-like receptor-4 is a target for suppression of proliferation and chemoresistance in HepG2 hepatoblastoma cells. Cancer Lett. 2015; 368(1):144-152. DOI: 10.1016/j.canlet.2015.08.004. View

Degirolamo C, Rainaldi S, Bovenga F, Murzilli S, Moschetta A . Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. Cell Rep. 2014; 7(1):12-8. DOI: 10.1016/j.celrep.2014.02.032. View

Hasan A, Rahman A, Kobori H . Interactions between Host PPARs and Gut Microbiota in Health and Disease. Int J Mol Sci. 2019; 20(2). PMC: 6359605. DOI: 10.3390/ijms20020387. View

Rajendran P, Li F, Shanmugam M, Vali S, Abbasi T, Kapoor S . Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1. J Cell Physiol. 2011; 227(5):2184-95. DOI: 10.1002/jcp.22954. View

Shi T, Wei J, Liu G, Han M, Liu T . [Researches on the change of intestinal barrier function in patients with ulcerative colitis]. Zhonghua Yi Xue Za Zhi. 2015; 95(24):1941-3. View

10.

Lu H, Wu Z, Xu W, Yang J, Chen Y, Li L . Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients. Microb Ecol. 2011; 61(3):693-703. DOI: 10.1007/s00248-010-9801-8. View

11.

Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M . Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science. 2018; 360(6391). PMC: 6407885. DOI: 10.1126/science.aan5931. View

12.

Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno G . Hepatocellualar carcinoma serum markers. Semin Oncol. 2012; 39(4):410-33. DOI: 10.1053/j.seminoncol.2012.05.001. View

13.

Yang J, Li M, Zheng Q . Emerging role of Toll-like receptor 4 in hepatocellular carcinoma. J Hepatocell Carcinoma. 2016; 2:11-7. PMC: 4918281. DOI: 10.2147/JHC.S44515. View

14.

Bibbo S, Ianiro G, Gasbarrini A, Cammarota G . Fecal microbiota transplantation: past, present and future perspectives. Minerva Gastroenterol Dietol. 2017; 63(4):420-430. DOI: 10.23736/S1121-421X.17.02374-1. View

15.

Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith R . Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006; 5(10):835-44. DOI: 10.1038/nrd2130. View

16.

Marlicz W, Wunsch E, Mydlowska M, Milkiewicz M, Serwin K, Mularczyk M . The effect of short term treatment with probiotic VSL#3 on various clinical and biochemical parameters in patients with liver cirrhosis. J Physiol Pharmacol. 2017; 67(6):867-877. View

17.

Wu L, Li J, Liu T, Li S, Feng J, Yu Q . Quercetin shows anti-tumor effect in hepatocellular carcinoma LM3 cells by abrogating JAK2/STAT3 signaling pathway. Cancer Med. 2019; 8(10):4806-4820. PMC: 6712453. DOI: 10.1002/cam4.2388. View

18.

Inagaki T, Moschetta A, Lee Y, Peng L, Zhao G, Downes M . Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A. 2006; 103(10):3920-5. PMC: 1450165. DOI: 10.1073/pnas.0509592103. View

19.

Zheng Y, Wang T, Tu X, Huang Y, Zhang H, Tan D . Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J Immunother Cancer. 2019; 7(1):193. PMC: 6651993. DOI: 10.1186/s40425-019-0650-9. View

20.

Schaap F, Trauner M, Jansen P . Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol. 2013; 11(1):55-67. DOI: 10.1038/nrgastro.2013.151. View